Please provide your email address to receive an email when new articles are posted on . Subcutaneous implantable cardioverter defibrillators can prevent arrhythmic death for people with congenital ...
ONAPGO, a subcutaneous infusion device, treats motor fluctuations in advanced Parkinson's disease and launches in the U.S. in 2025. Supernus Pharmaceuticals has announced the FDA approval of ONAPGO, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results